Condition

Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting0

Common interventions7

Lead sponsors shown3

Clinical trials

4 shown

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung CancerNCT02245100 · 2014-07-22

COMPLETED

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck CancerNCT01528137 · 2012-05-01

TERMINATED

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497 · 2003-08-01

COMPLETED

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckNCT00063895 · 2003-04-01

COMPLETED

Common interventions

Laboratory biomarker analysisOTHER3 Cytology specimenOTHER1 erlotinib hydrochlorideDRUG1 gefitinibDRUG1 pharmacogenomic studiesOTHER1 pharmacological studyOTHER1 talactoferrinBIOLOGICAL1

Leading sponsors

National Cancer Institute (NCI) 2 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 1 Stanford University 1

Trial status mix

COMPLETED3

TERMINATED1

Phase mix

PHASE12

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.